Cellectis (CLLS) Depreciation & Amortization (CF) (2015 - 2026)
Cellectis (CLLS) posted quarterly Depreciation & Amortization (CF) of $4.5 million for Q1 2026, down 8.03% year-over-year from $4.9 million in Q1 2025, and down 9.5% quarter-over-quarter from $5.0 million in Q3 2025.
Cellectis (CLLS) Depreciation & Amortization (CF) (2015 - 2026) Analysis & Trends
Cellectis' Depreciation & Amortization (CF) history runs 12 years deep, the most recent figure standing at $4.5 million for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 8.03% year-over-year to $4.5 million; the TTM figure through Mar 2026 stood at $14.6 million (up 1.28% YoY), while the FY2016 annual figure was $2.2 million, up 14.11% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $4.5 million, down from $5.0 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $5.0 million in Q2 2025, with the low at $4.3 million in Q3 2022.
- The 5-year median for Depreciation & Amortization (CF) is $4.6 million (2024), against an average of $4.7 million.
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) jumped 32.11% in 2022, then decreased 9.08% in 2023.
- Cellectis' Depreciation & Amortization (CF) stood at $4.3 million in 2022, then gained by 3.72% to $4.5 million in 2023, then gained by 5.69% to $4.7 million in 2024, then climbed by 6.17% to $5.0 million in 2025, then decreased by 9.5% to $4.5 million in 2026.
- Business Quant data shows CLLS's Depreciation & Amortization (CF) at $4.5 million in Q1 2026, $5.0 million in Q3 2025, and $5.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | 4.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.54 Mn |
| Mar 31, 2026 | 4.54 Mn |
| Sep 30, 2025 | 5.01 Mn |
| Sep 30, 2025 | 5.01 Mn |
| Jun 30, 2025 | 5.02 Mn |
| Jun 30, 2025 | 5.02 Mn |
| Mar 31, 2025 | 4.93 Mn |
| Mar 31, 2025 | 4.93 Mn |
| Sep 30, 2024 | 4.72 Mn |
| Sep 30, 2024 | 4.72 Mn |
| Jun 30, 2024 | 4.73 Mn |
| Jun 30, 2024 | 4.73 Mn |
| Mar 31, 2024 | 4.57 Mn |
| Mar 31, 2024 | 4.57 Mn |
| Sep 30, 2023 | 4.47 Mn |
| Sep 30, 2023 | 4.47 Mn |
| Jun 30, 2023 | 4.42 Mn |
| Jun 30, 2023 | 4.42 Mn |
| Mar 31, 2023 | 4.46 Mn |
| Mar 31, 2023 | 4.46 Mn |